North America To Hold The Dominant Position In The Global Blood Transfusion Devices Market Owing To The Increasing Demand For Blood Transfusion In The U.S.

 Key players operating in the blood transfusion devices market include Fresenius Kabi AG,  Grifols, S.A., Tenko International Group Corp, Terumo Corporation, Kawasumi Laboratories, Inc., Haemonetics Corporation, Bioelectronica MILANO, RAYS S.P.A., Macopharma SA, B. Braun Melsungen AG, Baxter International Inc., Neomedic Limited, and 3M Company.

The growing prevalence of blood-related disorders is fostering the growth of the blood transfusion devices market. As per estimates by the NIH and National Heart, Lung, and Blood Institute, blood transfusions are very common in the U.S., as each year, over 5 million Americans need blood transfusions, which increases the demand for blood transfusion devices. Increasing healthcare expenditure across developing regions is again propelling the growth of the blood transfusion devices market. According to the U.S. Centers for Medicare & Medicaid Services, National health spending is projected to grow at an average annual rate of 5.4 percent for 2019-28 and to reach $6.2 trillion by 2028. 

North America is expected to hold the dominant position in the global blood transfusion devices market and this is attributed to the increasing demand for blood transfusion in the U.S. For instance, according to the American National Red Cross, approximately 36,000 units of red blood cells are needed every day and around 21 million blood components are transfused each year in the U.S.

The human blood Transfusion Device market is expected to be largely driven by an increase in the number of acute kidney infections and a rise in the occurrence of multiple blood-borne diseases around the world. Moreover, recent technological developments in micro-fabricated infusion pumps, automated apheresis machines, blood collection and warming systems, and infusion pumps have facilitated the accessibility of highly purified and safe components for performing blood transfusions. Despite this, blood-borne pathogens continue to pose a significant risk for public health. This highlights the urgent need for developing new approaches and technologies for addressing this critical issue.

Key Developments:

    1 In April 2021, EryPharm launched a medical device product to mass-produce cultured red blood cells and develop new sourcing for blood transfusions. The product will improve the quality of life of multi-transfused patients who suffer from hereditary or acquired diseases of the red blood cells in particular, 

    2 In April 2019, Illinois-based Ecomed Solutions launched HEMAsavR, a blood management device that can be installed in operating theatres to collect a patient’s lost blood during surgery and return it to their body.